Heiskala et al. compared the levels of CCL2 and markers expressed by monocytes/macrophages (CD163, CD14, and the CCL2 receptor CCR2) in samples from CNBs to those from the corresponding resected tumors from 52 patients with primary BC. This evidence concerns the gene CCR2 and breast cancer.